Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|October 20, 2020||20/10/2020||Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT)||Tacrolimus Crossover Trial for Hereditary Hemorrhagic Telangiectasia (HHT)||Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed||Drug: Tacrolimus capsule (low-dose);Drug: Placebo||St. Michael's Hospital, Toronto||United States Department of Defense||Recruiting||18 Years||N/A||All||30||Phase 2||Canada|
|17/12/2019||30/09/2019||Tacrolimus for bleeding in hereditary hemorrhagic telangiectasia patients||An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia - Tacrolimus for bleeding in HHT patients||Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by mucocutaneous telangiectasis. Telangiectasis predominantly observed in the nasal mucosa and gut, and are abnormal, thin walled blood vessel that can easily rupture leading to hemorrhage. |
MedDRA version: 20.0;Level: LLT;Classification code 10038554;Term: Rendu-Osler-Weber syndrome;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|St. Antonius Hospital||NULL||Authorised-recruitment may be ongoing or finished|| Female: yes|
|20||Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no||Netherlands|